The fact
The move comes amid a sluggish IPO market, with investors remaining cautious.
The biotech sector hopes to reignite interest in public offerings.
Click the link to read an article on the topic:
The move comes amid a sluggish IPO market, with investors remaining cautious.
The biotech sector hopes to reignite interest in public offerings.